Prestieesci Research Review

A STUDY TO FIND OUT THE STEATOTIC LIVER DISEASE LINKED TO METABOLIC DYSFUNCTION AN EXPANSIVE VIEW ON A COMPLEX ISSUE

Dai Decai, Satheesh Babu Natarajan

Lincoln University College, 47301 Petaling Jaya, Selangor D. E., Malaysia.

Corresponding author: Dai Decai, Lincoln University College, 47301 Petaling Jaya, Selangor D. E., Malaysia, Email: 254958816@qq.com

ABSTRACT

Nonalcoholic fatty liver illness (the condition), which affects over 25% of the global population and over 60% of those at elevated risk, is becoming more and more common. It increases the risk of developing certain conditions linked to the liver and cardiovascular system as part of the metabolic syndrome. A multidisciplinary approach is necessary for the treatment of NAFLD because of the disease's complexity and the comorbidities and problems that often accompany it. However, there is a lack of knowledge Concerned among several experts on the gravity and potential consequences of fatty liver disease that is not alcoholic, as well as its comorbidities, consequences, and the necessary actions to take if NAFLD is detected. People with actively metabolising non-alcoholic steatosis (NASH) who have cirrhosis, inflexible simple steatosis, hepatocellular carcinoma, and cardiovascular disease must be identified. Unfortunately, there are conflicting recommendations for the best diagnostic and treatment methods, and this may be a challenging task. Here, we take a look back at NAFLD's origins, diagnoses, and treatment options before moving on to a discussion of potential future directions for multidisciplinary care path development.

Keywords: Steatotic Liver, Disease, Metabolic Dysfunction, Diagnostic.

INTRODUCTION

There has been a meteoric rise in the number of individuals adhering to the "Western lifestyle," which comprises consuming an excessive number of calories with no physical activity. A "Western lifestyle" is linked to obesity and metabolic syndrome, a group of symptoms involving hypertension, abnormal lipid profiles, high blood sugar, and an increase in abdominal fat. "Nonalcoholic fatty liver disease (NAFLD)" is a component of

metabolic syndrome that affects the liver. With no other hepatic steatosis causes, such as heavy alcohol consumption, specific metabolic abnormalities, or medicine use, imaging or histological findings showing intracellular fat accumulation in over 5% of hepatocytes characterise "Non-alcoholic fatty liver disease (NAFLD)". The epidemics of obesity and metabolic disorders have coincided with a dramatic rise in the prevalence of non-alcoholic fatty liver disease (NAFLD), which currently affects over 25% of the global population. Prevalence estimates exceed 60%5 in high-risk groups, including those with type 2 diabetes mellitus (T2DM). In addition to raising healthcare expenditures, quality of life, and death rates, "Non-alcoholic fatty liver disease (NAFLD)" and its comorbidities, such as type 2 diabetes and cardiovascular disease, also raise healthcare expenses. There is a continuum of disease phases that NAFLD covers. "Hepatocellular carcinoma (HCC)", cirrhosis, liver fibrosis, "Nonalcoholic fatty liver (NAFL)", and liver disease (NASH) are some of the stages that could appear. A small percentage of people with hepatic steatosis may have severe liver disease, even though "Nonalcoholic fatty liver disease (NAFLD)" is common. Liver failure, hepatic encephalopathy, oesophageal varices, ascites, and HCC are all possible consequences of NAFLD that has progressed to a more advanced stage of liver disease. While detecting non-progressive simple steatosis in people at low risk of these problems is less important, diagnosing metabolically active NASH in those at risk of heart attack, cirrhosis, and HCC is of greater importance. It may be difficult to identify these people at risk, and there are conflicting recommendations on the best way to diagnose and treat them. This means that many doctors don't know what to do when they suspect or have a fresh diagnosis of NAFLD. The lack of a unified healthcare strategy for NAFLD, which addresses the multifaceted nature and possible impact of this condition, is a key component of the issue (Henry L, 2022).



Figure 1: The range of symptoms associated with NAFLD is wide.

A thorough presentation of the diagnostic options, clinical care procedures, and recommendations for the development of an all-encompassing treatment plan are the goals of the individuals involved. The causes, symptoms, and treatment options for NAFLD (non-alcoholic fatty liver disease) are discussed here (Kowalski, 2019).

BACKGROUND

A new public health crisis, non-alcoholic fatty liver disease (NAFLD) is associated with substantial cardiometabolic comorbidities in patients. Everyone from the primary care physician to the vascular specialist, hepatologist, internist-endocrinologist, and assistant nurse must work together to identify patients who are at high risk for developing NASH. Efforts to establish a NASH workgroup have emerged in several medical facilities throughout the world in an effort to foster such cooperation. At the time of patient diagnosis with NAFLD, it is not always clear whether the patient has non-progressive simple steatosis, metabolically active NASH, cirrhosis, or HCC; the latter three groups are associated with an increased risk of cardiovascular disease and other serious complications. For improved screening and differentiation between liver disease stages, as well as for assessments of the likelihood of progression and progression of cirrhotic consequences, such as HCC, more precise and non-invasive diagnostic methods are required. Meanwhile, Fig. 2 offers suggestions for screening, diagnosis, and monitoring in (potential) NAFLD patients due to the lack of a commonly accessible, precise, non-invasive diagnostic instrument. Patients at high risk for nonalcoholic fatty liver disease (NAFLD) should undergo screening with ultrasonography or serum liver enzyme tests every three years. It is recommended to monitor HCC every six months if significant fibrosis or cirrhosis is present. It is also recommended to check for esophageal varices in cases with portal hypertension (Tamaki N, 2022).



Figure 2: Approaching non-alcoholic fats liver disease (NAFLD) from several perspectives.

PURPOSE OF THE STUDY

This study's main goal was to find out how faecal microbiota transplantation (FMT) affected individuals with metabolic syndrome-related non-alcoholic fatty liver disorder (NAFLD). With regard to treatment-naïve NAFLD patients, the research specifically sought to compare the results of autologous (from self) with allogeneic (from donors) FMT. Analyse how FMT affects many biological systems that are important for NAFLD, such as the makeup of the gut microbiota, plasma metabolomics, and the DNA methylation patterns of the liver. Create and verify a model using machine learning that can use these biological indicators to differentiate between heterologous and autologous FMT patients during a 24-week timeframe. help further knowledge regarding the gut-liver axis in nonalcoholic fatty liver disease (NAFLD) and its potential as a target for therapy. Examine the potential for predicting and customising FMT therapy responses in those with NAFLD using multi-omics data. Provide the baseline information needed for further, more extensive research on the effectiveness and workings of FMT in the treatment of NAFLD. By addressing these goals, the research aimed to further our knowledge of the pathophysiology and treatment of non-alcoholic fatty liver disease (NAFLD), with a focus on the involvement of the gut microbiota. It also paved the way for more individualised and successful therapies for this illness, which is becoming more and more common.

LITERATURE REVIEW

Liver cirrhosis, which mimics alcoholic hepatitis, may occur in individuals who do not drink excessively. Most of the patients were moderately obese and had diabetes mellitus. This liver condition is known as non-alcoholic steatohepatitis. After removing variables like heavy alcohol consumption, drugs that cause hepatic stenosis, and other ongoing liver disease causes, ultrasonography results may be used to define NAFLD (non-alcoholic fatty liver disease), according to the recommendations of the Asian-Pacific Sitting Party for NAFLD. The European Association for the Study of Liver (EASL) then released a position statement acknowledging that, although NAFLD had previously been diagnosed by ruling out other causes of chronic liver disease, its robust correlation with metabolic syndrome and overlap with other chronic liver disorders securely supported a rebranding. Although the term NAFLD was still in use in major international recommendations 4-6, a shift was imminent. Consider the EASL's 2016 guidelines, which defined NAFLD as "associated with metabolic risk factors" when they used the term "primary NAFLD." The Asian-Pacific Research Party published recommendations in 2017 that provided a "positive" definition of NAFLD (van Dijk, 2023).

Introduced a novel term, metabolic processes dysfunction-associated fatty liver condition (MAFLD), which may be diagnosed in adulthood who are overweight or obese, have steatosis of the liver identified by imaging, The bloodstream biomarkers, or liver

field of hist have had type 2 diabetes. (T2DM) or have a combination of metabolic risk abnormalities. This has received the endorsement of numerous international associations and organisations, including the Asian Pacific Association for the Statistical Investigation concerning the Liver and the Malaysian Society of Gastro and Hepatology. With the announcement of a multi-society Delphi compromise declaration on the new fatty liver disease terminology in June 2022, the term mitochondrial dysfunction-associated steatosis hepatitis disease was introduced, and the term NAFLD had been effectively retired. Given that the two terms are more comprehensive of the same situation, MAFLD and MASLD represent superior alternatives. (Mazi TA, 2018).

Table 1

Characteristic	MAFLD
Positive diagnostic criteria	Yes
Attributes the condition to its etiology	Yes
Criteria	Hepatic steatosis detected either by imaging techniqu
Presence of other concomitant liver diseases	Other concomitant liver diseases retain their own terr

*MetALD, i.e., weekly intake 140–350 g for female, 210–420 g for male (average daily 20–50 g for female, 30–60 g for male).

Abbreviations:
MAFLD: metabolic dysfunction-associated fatty liver disease
MASLD: metabolic dysfunction-associated steatotic liver disease
HDL: high-density lipoprotein
HbA1c: glycosylated hemoglobin
HOMA-IR: homeostatic model for assessment of insulin resistance
hs-CRP: high sensitivity C-reactive protein
BMI: body mass index
MetALD: MASLD and increased alcohol intake

Research Question

1. What are the long-term cardiovascular and metabolic consequences of MASLD, and how do they differ from those associated with other forms of liver disease?

METHODOLOGY

The LITMUS project, which aims to identify and verify a specified set of biomarkers for diagnosing NASH and NAFLD-related fibrosis, is an international multi-centre effort that this study is a part of. The average person may see the whole systematic review procedure. The PRISMA-DTA statement was used to create the present report.

Using a sophisticated search strategy, researchers looked through the literature sought studies that assessed Pro-C3's diagnostic accuracy in NAFLD patients. The search method included not only the whole record but also its title and abstract by using Medical Theme Heading terms. In 2022, searches were conducted using a number of databases, including MEDLINE (via OVID), EMBASE (via OVID as well), PubMed, Academic Citations Index, plus CENTRAL (the Cochrane Library). The supplement may provide the whole search strategy for the researchers. In order to find any more studies that the search strategy could have missed, they got in touch with the LITMUS colleagues and manually went through the bibliographies of research papers that qualified. In 2022, the search underwent updates. Up until then, it had examined every record that fit our search criteria.

CONCEPTUAL FRAMEWORK



RESULTS

In 21 treatment-naïve patients, hepatic steatosis and metabolic syndrome were treated with allogeneic (n = 10) and autologous (n = 11) FMT. Individuals with a history of cholecystectomy, diabetes, especially type 2, heart disease, renal disease, or compromised immune system function were excluded from the study. None of the individuals in the group took medication. The complete list of requirements for being included or excluded is available elsewhere. The starting points of the study participants are shown in Table 2. Most notably, there was no significant difference at baseline between the treatment groups' food intake or age (Suppl. Table 2). When it came to the NAFLD action score (NAS), fibrosis stage, and steatosis percentage at baseline, there were no statistically noticeable variations seen between the groups.

Table 2: Basic data regarding 21 individuals whose NAFLD was verified by biopsy. Data may be shown as the average plus or minus the standard deviation, which is midpoint

(interquartile range), or frequency (%). The results of many statistical tests, including the Mann-Whitney U examination for independent data, the t-test on information with a distribution that is typical, and the exact test used by Fisher for binary data, are reflected in the p-values. For glutamate transaminase, aspartate a protein called trans, and "BMI," respectively, the acronyms "ALP," "an ALT," and "AST" are used. The abbreviations for high-density lipoprotein lipid (LDL-C) and low-density lipoprotein chole (LDL-C) are the haemoglobin A and LDL-C, respectively. Alpha-lutamyltransferase, C-reactive protein, and faecal microbiota transplantation. The NAS score is the NAFLD activity score. Diabetes mellitus type 2, or T2DM for short.

Table 2

Characteristic	Autologous FMT (n=11)	Allogenic FMT (n=10)	p-value
Age, years	48.5 ± 10.2	51.2 ± 6.6	0.48
Sex, male/female	10/1	7/3	0.31
BMI, kg/m²	31.5 ± 4.8	31.7 ± 3.5	0.91
HbA1c, mmol/mol	37.6 ± 3.8	38.2 ± 3.7	0.70
Glucose, mmol/L	5.7 ± 0.5	5.8 ± 0.7	0.79
AST, IU/L	29.0 [26.5-33.0]	39.5 [37.0-49.5]	0.001
ALT, IU/L	48.1 ± 16.5	70.8 ± 23.4	0.02
ALP, IU/L	83.0 [54.0-120.5]	71.0 [58.8-76.8]	0.67
GGT, IU/L	41.1 ± 21.4	45.1 ± 19.3	0.66
Cholesterol, mmol/L	5.8 ± 1.6	6.0 ± 0.8	0.75
HDL-C, mmol/L	1.2 [1.0-1.4]	1.2 [1.0-1.4]	0.80
LDL-C, mmol/L	4.0 ± 1.3	4.2 ± 0.7	0.71
Triglycerides, mmol/L	1.2 ± 0.6	1.4 ± 0.5	0.41
CRP, mg/mL	2.2 [0.8-4.3]	1.5 [0.9-3.2]	0.50
Steatosis, %	35.0 ± 20.7	34.1 ± 20.4	0.92
NAS score			0.38
1	1 (9%)	0 (0.0%)	
2	5 (46%)	4 (40%)	
3	4 (36%)	2 (20%)	
4	1 (9%)	4 (40%)	
Necro-inflammation score			0.06
0	1 (9%)	0 (0%)	
1	10 (91%)	6 (60%)	
2	0 (0%)	4 (40%)	
Fibrosis stage			1.00
F0	3 (30%)	2 (20%)	
F1	6 (60%)	5 (50%)	
F2	2 (20%)	2 (20%)	
F3	0 (0%)	1 (10%)	

The predictive machine learning model effectively differentiated between allogenic and allogeneic FMT patients between 0 and 24 weeks by examining changes to the intestinal microbiota (AUC 0.78), plasma metabolomics (AUC 0.74), the liver methylation of DNA patterns (AUC 0.75). The permutation study's findings showed that the likelihood that the obtained accuracy was the product of chance was very low (0.88; $p< 0.001$). The key distinguishing characteristics amongst all the groups in each research are described below.

DISCUSSION

This work sheds light on the possibility of intestinal microbiota transplantation to treat NAFLD and metabolic syndrome. A study examined allogeneic vs autologous FMT in 21 inexperienced individuals with biopsy-confirmed NAFLD. A neural network (ML) algorithm that can discriminate autologous and autologous patients is a major result. We differentiated according to modifications to gut microbiota over 24 weeks (AUC0.78), plasma metabolomics (AUC0.74), and patterns of DNA methylation in the liver (AUC 0.75). An accurate model, verified by permutations testing (0.88; $p< 0.001$), indicates that FMT has a significant and predictable influence on NAFLD-related biological systems. These indicators may distinguish allogeneic and autologous FMT patients, indicating that the transplanted microbiota source greatly affects the host's biological response. This discovery may help physicians determine whether NAFLD patients could benefit most from allogeneic or autologous FMT. The study's modest sample size (n=21) excluded participants with NAFLD comorbidities such as diabetes type 2 and cardiovascular disease. This made the research more controlled, but it may restrict its applicability to NAFLD. The study's emphasis on gut microbiota, plasma metabolomics, and liver DNA methylation gives a complete picture of FMT's systemic effects in NAFLD patients. This multi-omics approach supports the expanding knowledge of NAFLD as a complex, multifactorial illness including metabolic, genetic, and environmental variables. The post-treatment differences between the heterologous and autologous groups in NAFLD severity, age, and food consumption are supported by the absence of substantial baseline differences. The FMT intervention may have caused the alterations, not pre-existing group differences. The study shows FMT's promise in NAFLD therapy, but further research is needed. Continuous follow-up studies would help determine the persistence of the identified alterations and their clinical importance for NAFLD development and outcomes. The study shows FMT's promise in NAFLD therapy, but further research is needed. The long-term ongoing research would assist to determine the persistence of the identified alterations and their clinical importance for NAFLD development and outcomes.

CONCLUSION

In light of the findings of this study, a novel approach to predicting treatment response has been developed via the use of machine learning and data from several omics. The findings of this research also give information that is promising for the use of FMT in the medical management of non-alcoholic fatty liver disorder. This work adds to the expanding literature on the gut-liver relationship in NAFLD, and its results open up new possibilities for tailoring treatments to the specific needs of people with this increasingly common disorder.

REFERENCES

1. Henry L, Paik J, Younossi ZM. Review article: the epidemiologic burden of non-alcoholic fatty
2. liver disease across the world. Aliment Pharmacol Ther [Internet]. 2022 Sep 1;56(6):942–56.
3. Available from: https://doi.org/10.1111/apt.17158
4. Kowalski MH, Qian H, Hou Z, Rosen JD, Tapia AL, Shan Y, et al. Use of >100,000 NHLBI
5. Trans-Omics for Precision Medicine (TOPMed) Consortium whole genome sequences
6. improves imputation quality and detection of rare variant associations in admixed African
7. and Hispanic/Latino populations. PLoS Genet. 2019 Dec;15(12):e1008500.
8. Mazi TA, Borkowski K, Newman JW, Fiehn O, Bowlus CL, Sarkar S, et al. Ethnicity-specific alterations of plasma and hepatic lipidomic profiles are related to high NAFLD rate and severity in Hispanic Americans, a pilot study. Free Radic Biol Med. 2021 Aug;172:490–502.
9. Tamaki N, Ahlholm N, Luukkonen PK, Porthan K, Sharpton SR, Ajmera V, et al. Risk of
10. advanced fibrosis in first-degree relatives of patients with nonalcoholic fatty liver disease.
11. J Clin Invest. 2022 Nov;132(21).
12. van Dijk A-M, Vali Y, Mak AL, Galenkamp H, Nieuwdorp M, van den Born B-J, et al.
13. Noninvasive tests for nonalcoholic fatty liver disease in a multi-ethnic population: The
14. HELIUS study. Hepatol Commun. 2023 Jan;7(1):e2109.